Research programme: kinase-directed anti-HIV agents - GPC Biotech/Galapagos

Drug Profile

Research programme: kinase-directed anti-HIV agents - GPC Biotech/Galapagos

Latest Information Update: 22 Jan 2007

Price : $50

At a glance

  • Originator Galapagos NV; GPC Biotech AG
  • Class
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
  • 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
  • 22 Jul 2002 Preclinical trials in HIV infections treatment in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top